Aribio "GlobalData Selects AR1001 as the Most Anticipated Alzheimer's Disease Treatment"

Aribio, which is pursuing a merger with Solux, announced on the 9th that the UK data analysis and consulting firm GlobalData selected AR1001 as the "most promising and commercially viable Alzheimer's disease treatment."

GlobalData released three reports: △Global Alzheimer's disease incidence △Analysis and forecast of treatment markets in major countries △Analysis of Alzheimer's disease treatment markets in 68 countries. According to GlobalData, currently, Leqembi and Kisunla are the only treatments available, but in the future, 12 treatments including Aribio's AR1001 are expected to enter the market in earnest. AR1001 was selected particularly because of its new drug mechanism, positive preclinical and Phase 2 clinical results, and excellent ease of administration.

The report also disclosed clinical and business comparison data with the existing treatment Leqembi. Among pipelines entering Phase 3 clinical trials, AR1001 scored the highest and achieved a high commercial score. Clinical and commercial scores were calculated based on efficacy, safety, tolerability, cost, marketing, and corporate reputation, respectively.

Additionally, GlobalData projected that the number of Alzheimer's patients in eight major countries (United States, China, France, Germany, Italy, Spain, United Kingdom, Japan) will increase from approximately 15.98 million in 2023 to 22.51 million in 2033. Among them, China is expected to have the highest number of patients at 10.4 million in 2033.

A company official stated, "We are honored to have objectively proven the competitiveness of AR1001 through a global evaluation agency," and added, "We will proceed with the ongoing Phase 3 clinical trial of AR1001, which began with the U.S. Food and Drug Administration (FDA) in 2022, without any setbacks."

This content was produced with the assistance of AI translation services.